NCT02371603COMPLETEDanonymous

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

GSK1278863

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet

Related intelligence directories

Indication directory: Anaemia Modality directory: small molecule Target directory: GSK1278863

Source & freshness

Source record

NCT ID

NCT02371603

Original source

ClinicalTrials.gov

Source last updated

Nov 17, 2017

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02371603

Title

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

PHASE1

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

GSK1278863

Target normalized

GSK1278863

Interventions

GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet

Public preview

Source record

This clinical trial, sponsored by GlaxoSmithKline, evaluated the drug-drug interaction potential of GSK1278863 with pioglitazone and rosuvastatin in healthy volunteers. The study was designed to assess pharmacokinetics and safety profiles of GSK1278863 when co-administered with these drugs, which are known substrates of CYP2C8 and OATP1B1.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Source & freshness

Public preview

Create an account to unlock this report

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts